- Home
- DTSS vs ABVC Comparison
DTSS vs ABVC Comparison
Compare DTSS & ABVC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DTSS
- ABVC
- Stock Information
- Founded
- DTSS 2014
- ABVC 2015
- Country
- DTSS China
- ABVC United States
- Employees
- DTSS N/A
- ABVC N/A
- Industry
- DTSS Computer Software: Prepackaged Software
- ABVC Biotechnology: Pharmaceutical Preparations
- Sector
- DTSS Technology
- ABVC Health Care
- Exchange
- DTSS Nasdaq
- ABVC Nasdaq
- Market Cap
- DTSS 14.2M
- ABVC 16.7M
- IPO Year
- DTSS N/A
- ABVC N/A
- Fundamental
- Price
- DTSS $2.13
- ABVC $0.98
- Analyst Decision
- DTSS
- ABVC
- Analyst Count
- DTSS 0
- ABVC 0
- Target Price
- DTSS N/A
- ABVC N/A
- AVG Volume (30 Days)
- DTSS 53.5K
- ABVC 655.9K
- Earning Date
- DTSS 05-12-2025
- ABVC 04-15-2025
- Dividend Yield
- DTSS N/A
- ABVC N/A
- EPS Growth
- DTSS N/A
- ABVC N/A
- EPS
- DTSS N/A
- ABVC N/A
- Revenue
- DTSS $47,284,153.00
- ABVC $509,588.00
- Revenue This Year
- DTSS N/A
- ABVC $735.18
- Revenue Next Year
- DTSS N/A
- ABVC N/A
- P/E Ratio
- DTSS N/A
- ABVC N/A
- Revenue Growth
- DTSS 117.51
- ABVC 234.31
- 52 Week Low
- DTSS $1.63
- ABVC $0.40
- 52 Week High
- DTSS $8.56
- ABVC $1.73
- Technical
- Relative Strength Index (RSI)
- DTSS 55.94
- ABVC 56.38
- Support Level
- DTSS $1.84
- ABVC $0.81
- Resistance Level
- DTSS $2.27
- ABVC $1.00
- Average True Range (ATR)
- DTSS 0.15
- ABVC 0.16
- MACD
- DTSS 0.03
- ABVC -0.01
- Stochastic Oscillator
- DTSS 78.13
- ABVC 39.92
About DTSS Datasea Inc.
Datasea Inc is a technology company. Its offers provides acoustic business services (focusing on high-tech acoustic technologies and applications such as ultrasound, infrasound, and Schumann resonance), 5G application services (5G AI multimodal digital business), and other products and services to various corporate and individual customers. The business activity of the group functions through China.
About ABVC ABVC BioPharma Inc.
ABVC BioPharma Inc is a clinical-stage biopharmaceuticals company with an active pipeline of six drugs and one medical device (ABV-1701/Vitargus) under development. For its drug products, it is focused on utilizing its licensed technology to conduct proof-of-concept trials through Phase II of the clinical development process. The firm is specialized in botanically based solutions that deliver high efficacy with low toxicity for improved health outcomes.